BioCentury
ARTICLE | Company News

Oberland Capital Management LLC, Agenus deal

October 19, 2015 7:00 AM UTC

Agenus sold its royalty stream on sales of shingles vaccine HZ/su and malaria vaccine RTS,S ( Mosquirix) to Oberland for a $100 million note. Agenus will receive an additional $15 million note if FDA approves HZ/su, a recombinant vaccine against varicella zoster virus, by before June 30, 2018. The vaccines use Agenus’ QS-21 adjuvant and are owned by GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.). Agenus was receiving low single-digit royalties on net sales of RTS,S from GSK. ...